Re-test your knowledge
Re-test your knowledge
Summary
Now that you have completed Module 6 The impact of insomnia, you should have a better understanding of the risk factors influencing the development of chronic insomnia, and its direct and indirect consequences to patients, the healthcare system and the economy. To test your knowledge, answer the questions below and see how your score has improved.
Congratulations on completing the course
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.3
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com
References
- Hafner M, Romanelli R J et al. The societal and economic burden of insomnia in adults: an international study. RAND Corporation, 2023
- Bhaskar S, Hemavathy D, Prasad S. Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities. J Family Med Prim Care 2016;5(4):780-784
- QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00658 | Date of preparation: September 2025
